Elefante Mark B boosted its position in Novartis AG (NYSE:NVS) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,019 shares of the company’s stock after buying an additional 400 shares during the period. Novartis AG accounts for 4.1% of Elefante Mark B’s investment portfolio, making the stock its 10th largest position. Elefante Mark B’s holdings in Novartis AG were worth $502,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Howe & Rusling Inc. boosted its position in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the period. City Holding Co. boosted its position in Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares during the period. TCI Wealth Advisors Inc. boosted its position in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the period. Archford Capital Strategies LLC boosted its position in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC boosted its position in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the period. 11.27% of the stock is currently owned by institutional investors and hedge funds.

Novartis AG (NYSE NVS) opened at 83.35 on Friday. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The firm has a market cap of $195.28 billion, a price-to-earnings ratio of 30.43 and a beta of 0.73. The stock has a 50 day moving average of $84.17 and a 200 day moving average of $78.68.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. During the same quarter last year, the firm earned $1.23 earnings per share. Novartis AG’s quarterly revenue was down 1.8% on a year-over-year basis. Equities research analysts predict that Novartis AG will post $4.73 EPS for the current fiscal year.

WARNING: “Elefante Mark B Purchases 400 Shares of Novartis AG (NYSE:NVS)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/elefante-mark-b-purchases-400-shares-of-novartis-ag-nysenvs.html.

NVS has been the subject of a number of research analyst reports. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, April 18th. Vetr cut shares of Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price for the company. in a research note on Tuesday, April 25th. Zacks Investment Research upgraded shares of Novartis AG from a “strong sell” rating to a “hold” rating in a research note on Monday, May 1st. UBS AG reiterated a “neutral” rating on shares of Novartis AG in a research note on Wednesday, May 24th. Finally, Morgan Stanley reiterated a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $83.56.

In other news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.01% of the stock is owned by company insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.